<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325245</url>
  </required_header>
  <id_info>
    <org_study_id>FRAIL-01</org_study_id>
    <nct_id>NCT02325245</nct_id>
  </id_info>
  <brief_title>Effects of Metformin in Pre-frail Elderly</brief_title>
  <official_title>Randomized-Controlled Trial of Metformin to Prevent Frailty in Pre-frail Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of metformin to prevent frailty in
      pre-frail non-diabetic elderly. Several outcomes measured in this study are frailty status,
      quality of life, handgrip strength, gait speed, and serum myostatin levels.

      We hypothesize that metformin for 16 weeks could prevent frailty in pre-frail elderly.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in frailty status at 16 weeks</measure>
    <time_frame>Baseline and at 16 weeks</time_frame>
    <description>Measurement: Frailty Index 40 items</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in health-related quality of life (HrQoL) at 16 weeks</measure>
    <time_frame>Baseline and at 16 weeks</time_frame>
    <description>Measurement: EQ-5D (with permission)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in handgrip strength at 16 weeks</measure>
    <time_frame>Baseline and at 16 weeks</time_frame>
    <description>Measurement: handgrip dynamometer (Jamar Hydraulic Hand Dynamometer Model J00105)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in gait speed at 16 weeks</measure>
    <time_frame>Baseline and at 16 weeks</time_frame>
    <description>Measurement: 15-feet walking test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum myostatin levels at 16 weeks</measure>
    <time_frame>Baseline and at 16 weeks</time_frame>
    <description>Measurement: ELISA test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pre-frail Elderly</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablet 500 mg three times a day for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet three times a day for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>CAS Number: 657-24-9</other_name>
    <other_name>ATC Code: A10BA02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pre-frail elderly;

          2. Capable to understand and carry-out the instruction.

        Exclusion Criteria:

          1. Unwilling to join the study;

          2. Diabetes mellitus (oral glucose tolerance test);

          3. Abbreviated Mental Test (AMT) score &lt; 8;

          4. Geriatric Depression Scale (GDS) score &gt;= 10;

          5. Body mass index (BMI) &lt;18,5 Kg/m2;

          6. Malnutrition (according to Mini Nutritional Assessment/MNA);

          7. Liver cirrhosis, severe liver dysfunction, or serum ALT levels &gt;3 times upper normal
             limit;

          8. Acute illness during inclusion period, eg. pneumonia, pain due to acute arthritis
             (visual analog scale &gt;6/10), stroke attack, crisis hypertension;

          9. Severe cardiac dysfunction: acute decompensated heart failure and/or chronic heart
             failure functional class III or IV (New York Heart Association classification);

         10. Severe pulmonary dysfunction: acute exacerbation of chronic obstructive lung disease
             stage III or IV (GOLD classification), and/or PaO2 levels &lt; 60 mmHg;

         11. Allergy to metformin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Purwita Laksmi, MD,SpPD-KGer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Geriatrics, Department of Internal Medicine, Universitas Indonesia-Cipto Mangunkusumo General Hospital, Jakarta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cipto Mangunkusumo General Hospital</name>
      <address>
        <city>Central Jakarta</city>
        <state>Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Purwita Laksmi, MD</last_name>
      <phone>+62-21-3918301</phone>
      <email>pwlaksmi@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Sumantri S, Setiati S, Purnamasari D, Dewiasty E. Relationship between metformin and frailty syndrome in elderly people with type 2 diabetes. Acta Med Indones. 2014 Jul;46(3):183-8.</citation>
    <PMID>25348180</PMID>
  </reference>
  <reference>
    <citation>Wang CP, Lorenzo C, Espinoza SE. Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 Diabetes. J Endocrinol Diabetes Obes. 2014;2(2). pii: 1031.</citation>
    <PMID>25506599</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Purwita Wijaya Laksmi</investigator_full_name>
    <investigator_title>Purwita Wijaya Laksmi, MD, SpPD-KGer</investigator_title>
  </responsible_party>
  <keyword>Frailty</keyword>
  <keyword>Pre-frailty</keyword>
  <keyword>Metformin</keyword>
  <keyword>Elderly</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Handgrip</keyword>
  <keyword>Gait speed</keyword>
  <keyword>Myostatin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 27, 2017</submitted>
    <returned>March 22, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

